Close Menu

NEW YORK (GenomeWeb) – A new study contributes to growing data indicating that liquid biopsy testing used in the early weeks or months of cancer treatment can help identify patients that are responding and will likely have better outcomes versus those that will not and might be better served by switching to another drug or other therapy.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.